SCHEMBL29386286

SCHEMBL29386286

c1ccc(Nc2nccc(-c3cncs3)n2)nc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK4 P11802 3/20 0.49
CCND1 P24385 2/20 0.49
CDK1 P06493 2/20 0.49
CDK2 P24941 2/20 0.49
CCNB1 P14635 1/20 0.49
CCNA2 P20248 1/20 0.49
CCNA1 P78396 1/20 0.49
CD38 P28907 1/20 0.48
NPC1 O15118 7/20 0.43
RAB9A P51151 7/20 0.43
TP53 P04637 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
LMNA P02545 2/20 0.43
MAPT P10636 2/20 0.43
NFKB1 P19838 2/20 0.43
NFKB2 Q00653 2/20 0.43
RELA Q04206 2/20 0.43
MAPK1 P28482 1/20 0.43
TDP1 Q9NUW8 1/20 0.42
MAPK13 O15264 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20455525 1.00 CDK4 (0.49) CDK4CCND1CDK1CDK2CCNB1
SCHEMBL2088047 0.83 PRKCD (0.59) CDK4CDK1CDK2CCNB1CD38
SCHEMBL2819228 0.76 CDK4 (0.54) CDK4CCND1CDK1CDK2CCNB1
SCHEMBL327377 0.76 PIM1 (0.50) NPC1RAB9ATP53SMN1; SMN2LMNA
SCHEMBL29557417 0.75 ABL1 (0.72) CDK4CCND1CDK1CDK2CCNB1
SCHEMBL1849187 0.75 SYK (0.62) CDK4CCND1CDK1CDK2CCNB1
SCHEMBL2513836 0.72 PIM1 (0.58) CD38NPC1RAB9ATP53SMN1; SMN2
SCHEMBL18936841 0.72 MEN1 (0.53) CD38NPC1RAB9ATP53SMN1; SMN2
SCHEMBL2321728 0.70 CDK4 (0.52) CDK4CCND1CDK1CDK2CCNB1
SCHEMBL16205256 0.70 CD38 (0.60) CD38NPC1RAB9ATP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250059178-A1 N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS Aucentra Thereapeutics Pty LTD (AU) 2025-02-20 US disclosed
EP-3957637-B1 N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS AUCENTRA THERAPEUTICS PTY LTD (AU) 2023-06-28 EP disclosed
EP-3331880-B3 N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS AUCENTRA THERAPEUTICS PTY LTD (AU) 2023-01-11 EP disclosed
US-20220267315-A1 N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS AUCENTRA THERAPEUTICS PTY LTD (AU) 2022-08-25 US disclosed
CN-110418789-B Derivatives of N-cycloalkyl/heterocycloalkyl-4- (imidazo [1,2-a ] pyridine) pyrimidin-2-amines as therapeutic agents 常州千红生化制药股份有限公司 2022-03-25 CN disclosed
EP-3957637-A1 N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS Aucentra Therapeutics Pty Ltd (AU) 2022-02-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250059178-A1 N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS CDK4, CDK6, CDK2 CDK4 1/4885CCND1 14/4885CDK1 11/4885
US-20220267315-A1 N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS CDK4, CDK6, CDK3 CDK4 1/4885CCND1 18/4885CDK1 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.